Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillation for the Treatment of Parkinson's Disease
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Umbilical cord-derived allogeneic mesenchymal stem cell therapy-Vitro Biopharma (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
- 17 Apr 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
- 27 Jan 2022 Status changed from recruiting to not yet recruiting.